Syphilis Testing Market: Public Health Screening Programs, Rapid Testing & Market Growth

According to IMARC Group's latest research publication, The global syphilis testing market size reached USD 1.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.9% during 2025-2033.

How AI is Reshaping the Future of Syphilis Testing Market

• AI Helps Doctors Detect Syphilis from Images: AI systems can look at medical photos of skin lesions and help doctors tell whether a patient has syphilis or another skin condition. These systems are highly accurate, correctly identifying syphilis in about 86% of cases. When AI combines image analysis with patient information, it becomes even more reliable, helping doctors diagnose infections faster and more accurately.
• AI Identifies High-Risk Patients Faster: AI tools can analyze patient data such as age, behavior patterns, and test results to identify people who are more likely to have syphilis. These systems can find high-risk groups that test positive more than 12 times as often as average-risk groups. This helps healthcare providers focus testing and treatment where it is most needed, saving time and resources.
• AI Predicts and Tracks Disease Outbreaks: AI can monitor data from medical records and even social media to spot early signs of rising syphilis cases. By identifying high-risk areas and behaviors, these tools help public health agencies respond more quickly to outbreaks and take action before the disease spreads further.

Request a Sample Report with the Latest Data & Forecasts

Syphilis Testing Industry Overview:

Syphilis cases are increasing rapidly around the world, creating serious challenges for healthcare systems. In the United States, more than 2.2 million sexually transmitted infections (STIs) were reported. Congenital syphilis (syphilis passed from mother to baby) has risen sharply—nearly seven times higher over the past 10 years. This shows a strong and urgent need for better and more widely available syphilis testing. Globally, the World Health Organization (WHO) estimates that over 1 million STIs are acquired every day, including about 8 million new syphilis infections each year. These alarming numbers are driving demand for faster, more accurate, and more accessible testing solutions.

Syphilis Testing Market Trends & Drivers

Governments and health agencies are taking action to control the spread of syphilis. In the U.S., the Centers for Disease Control and Prevention (CDC) released its first-ever comprehensive guidelines for syphilis testing, helping labs follow clear and standardized procedures. Many U.S. states now require syphilis screening during pregnancy due to rising congenital syphilis cases. On a global level, 95 countries have added combined HIV and syphilis rapid tests to their national health policies. Most countries also have programs aimed at preventing mother-to-child transmission. In addition, national health plans and telehealth programs are expanding access to STI testing, making it easier for people to get tested even in remote or underserved areas.

There is strong growth in point-of-care and rapid syphilis testing. New FDA-approved tests allow healthcare providers to deliver accurate results more quickly. Some rapid tests can even be used outside traditional labs, making them useful in clinics, emergency rooms, and correctional facilities. Affordable self-testing options are also emerging, helping reduce stigma and encouraging more people to get tested. At the same time, major diagnostic companies are investing heavily in new technologies to improve test accuracy and speed.

Healthcare systems are modernizing how syphilis testing is delivered. Advanced testing methods now offer better accuracy than older techniques. Hospitals are adopting opt-out testing models, meaning patients are tested automatically unless they decline—this significantly increases screening rates, especially among pregnant women. Digital health platforms and telemedicine services are integrating STI testing with HIV prevention programs. Education and awareness campaigns are encouraging regular testing among high-risk groups, such as men who have sex with men and transgender communities. Overall, the continued global rise in syphilis and other STIs is driving strong demand for testing solutions that are easy to access, reliable, and effective in supporting early diagnosis and timely treatment.

Leading Companies Operating in the Global Syphilis Testing Industry:

• Abbott Laboratories
• Becton Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• DRG International Inc. (BioCheck Inc.)
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG (Siemens AG)
• Thermo Fisher Scientific Inc.

Syphilis Testing Market Report Segmentation:

By Type:

• Primary and Secondary Syphilis
• Latent and Tertiary Syphilis

Primary and secondary syphilis represents the largest segment, as early-stage detection is critical for preventing disease progression and reducing transmission.

By Location of Testing:

• Laboratory Testing
• Point-of-Care (POC) Testing

Laboratory testing dominates the market due to established infrastructure, automation capabilities, and comprehensive testing algorithms required for accurate diagnosis.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America exhibits clear dominance in the syphilis testing market due to high disease prevalence, advanced healthcare infrastructure, significant R&D investments, and comprehensive screening programs.

Recent News and Developments in Syphilis Testing Market

• January 2025: Bio-Rad Laboratories invested USD 50 million in its molecular diagnostics division to develop new syphilis testing solutions, aiming to enhance its presence in the global infectious disease testing market and deliver next-generation diagnostic platforms.
• July 2025: Health Canada approved MedMira's Multiplo TP/HIV rapid test for investigational use, paving the way for self-testing and non-professional testing. This initiative, supported by clinical research from REACH Nexus, aims to improve early detection and response to growing HIV and syphilis cases.
• August 2024: Hologic received FDA approval for its Panther Fusion Syphilis Total assay, a fully automated platform designed to improve the accuracy and efficiency of syphilis testing in laboratories, enabling high-throughput screening with enhanced reliability.
• October 2024: Chembio Diagnostics highlighted its DPP rapid tests, including the HIV-Syphilis combo, at the SCASM conference in La Jolla and the National Conference on Correctional Health Care in Las Vegas, emphasizing advantages of point-of-care testing for faster screening.
• February 2024: CDC published comprehensive Laboratory Recommendations for Syphilis Testing, providing the first-ever official guidelines on serologic algorithms, treponemal tests, nontreponemal tests, and molecular detection methods for laboratory directors and clinical staff nationwide.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.